Dr Ibrahim Ali

Dr Ibrahim Ali


BSc(Hons):                              Imperial College, London, 2008

MBBS:                                     Imperial College, London, 2010

Fellow:                                    Higher Education Academy, 2012

MRCP:                                     Royal College of Physicians, 2014

MSc (Medical Education):       University of Manchester, 2017

PhD:                                        University of Manchester, 2021


Present appointments 

Consultant Nephrologist and Acute Physician, Northern Care Alliance NHS Foundation Trust:  2022-present

Honorary Senior Lecturer in Cardiovascular Sciences, School of Medical Sciences, University of Manchester:  2023-present

Educational supervisor, Joint Royal Colleges of Physicians Training Board: 2022-present

Member of the UK Kidney Association KFRE Implementation Group: 2021-present


Previous appointments 

Renal registrar training, North West Deanery: 2014-2022

North West Deanery renal trainee representative: 2017-18

Clinical research fellow, Salford Royal Hospital: 2018-2021

Associate College Tutor, Fairfield General Hospital: 2021-22


Research interests/expertise

  • CKD progression
  • Risk prediction modelling
  • Pre-dialysis care
  • Transitional care

Current research grants 

 Application pending to Kidney Research UK.


Publications (last 5 years)


Medina CRR, Ali I, Baricevic-Jones I, Odudu A, Saleem MA, Whetton AD et al. Proteomic signature associated with chronic kidney disease (CKD) progression identified by data-independent acquisition mass spectrometry. Clin. Proteomics. 2023;20(1):19. 


Ali I, Green D, Kalra P, Kalra PA. Experience of a bespoke hyperkalaemia clinic to facilitate prescribing of renin-angiotensin-aldoseterone system inhibitors in patients with heart failure with reduced ejection fraction. CardioRenal Med. 2022;12:196-204.


Zacharias HU, Altenbuchinger M. Schultheiss UL, Raffler J, Kotsis F, Ghasemi S, Ali I et al. A predictive model for progression of CKD to kidney failure based on routine laboratory tests. Am J Kidney Dis. 2021;79:217-230.

 Ali I, Donne RL, Kalra PA. A validation study of the kidney failure risk equation in advanced chronic kidney disease according to disease aetiology with evaluation of discrimination, calibration and clinical utility. BMC Nephrol. 2021; 22:57.

Wickens O, Chinnadurai R, Mannan F, Svendsen F, Baig MY, Chukwu C, Ali I et al. Investigating the utility of COVID-19 antibody testing in end-stage renal disease patients receiving haemodialysis: a cohort study in the United Kingdom. BMC Nephrol. 2021;22:154.

 Ali I, Chinnadurai R, Ibrahim ST, Kalra PA. Adverse outcomes associated with rapid linear and non-linear patterns of chronic kidney disease progression. BMC Nephrol. 2021;22:82.

 Sharma V, Ali I, Veer SVD, Martin G, Ainsworth G, Augustine T. Adoption of clinical risk prediction tools is limited by a lack of integration with electronic health records. BMJ Health Care Inform. 2021;28:e100253.

 Ali I, Kalra PA. A validation study of the 4-variable and 8-variable kidney failure risk equation in transplant recipients in the United Kingdom. BMC Nephrol. 2021;22:57.


Lodge MDS, Abeygunaratne T, Alderson H, Ali I, et al. Safely reducing haemodialysis frequency during the COVID-19 pandemic. BMC Nephrol. 2020;21:532. 

 Ali I, Ibrahim ST, Chinnadurai R, Green D, Taal M, Whetton TD, Kalra PA. A paradigm to discover biomarkers associated with chronic kidney disease progression. Biomarker Insights. 2020;15:1-5.

 Ali I, Chinnadurai R, Cornea G, Intorcia M, Kalra PA. The role of patiromer: comparing OPAL-HK data with untreated real-world patients in the United Kingdom – a retrospective, propensity-matched analysis. PLoS ONE. 2020;15:e0237467. 

 Ali I, Chinnadurai R, Ibrahim ST, Green DA, Kalra PA. Predictive factors of rapid linear renal progression and mortality in patients with chronic kidney disease. BMC Nephrol. 2020; 21:345.

Ibrahim ST, Chinnadurai R, Ali I, et al. Genetic polymorphism in C3 is associated with progression in chronic kidney disease (CKD) patients with IgA nephropathy but not in other causes of CKD. PLoS ONE. 2020;15:e0228101.


Ali I, Kalra PA. Risk prediction in chronic kidney disease. Curr Opin Nephrol Hypertens. 2019;28:1.

Skip to content